Synlogic Discontinues SYNB1020 Development For Treating Hyperammonemia

(RTTNews) - Clinical stage company Synlogic, Inc. (SYBX) announced Tuesday that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia.

The company said the results from its Phase 1b/2a study of SYNB1020 did not demonstrate an activity profile in ammonia lowering that warranted continued development of the program.

The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia.

The study was designed to evaluate the safety and tolerability of SYNB1020 treatment, as well as changes in blood ammonia levels and several exploratory endpoints associated with early stage hepatic encephalopathy (HE).

The company added that it will now focus its resources on advancement of SYNB1618 for the treatment of phenylketonuria, SYNB1891 for the treatment of solid tumors and several new programs in early development.